Literature DB >> 23543152

Multiple myeloma: so much progress, but so many unsolved questions.

Philippe Moreau, Stéphane Minvielle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23543152      PMCID： PMC3659977          DOI： 10.3324/haematol.2013.083592

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Authors:  Annemiek Broyl; Dirk Hose; Henk Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; H Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

3.  Minor clone provides a reservoir for relapse in multiple myeloma.

Authors:  F Magrangeas; H Avet-Loiseau; W Gouraud; L Lodé; O Decaux; P Godmer; L Garderet; L Voillat; T Facon; A M Stoppa; G Marit; C Hulin; P Casassus; M Tiab; E Voog; E Randriamalala; K C Anderson; P Moreau; N C Munshi; S Minvielle
Journal:  Leukemia       Date:  2012-08-09       Impact factor: 11.528

4.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Authors:  Marco Ladetto; Gloria Pagliano; Simone Ferrero; Federica Cavallo; Daniela Drandi; Loredana Santo; Claudia Crippa; Luca De Rosa; Patrizia Pregno; Mariella Grasso; Anna Marina Liberati; Tommaso Caravita; Francesco Pisani; Tommasina Guglielmelli; Vincenzo Callea; Pellegrino Musto; Clotilde Cangialosi; Roberto Passera; Mario Boccadoro; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

6.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Authors:  Bijay Nair; Frits van Rhee; John D Shaughnessy; Elias Anaissie; Jackie Szymonifka; Antje Hoering; Yazan Alsayed; Sarah Waheed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

7.  The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Gema Mateo; Jose J Pérez; Maria Angeles Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de las Heras; Maria Victoria Mateos; Maria Consuelo López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Yolanda González; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San-Miguel
Journal:  Blood       Date:  2009-09-15       Impact factor: 22.113

8.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Authors:  Olivier Decaux; Laurence Lodé; Florence Magrangeas; Catherine Charbonnel; Wilfried Gouraud; Pascal Jézéquel; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Régis Bataille; Loïc Campion; Hervé Avet-Loiseau; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

9.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

10.  Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.

Authors:  Nicholas J Dickens; Brian A Walker; Paola E Leone; David C Johnson; José L Brito; Athanasia Zeisig; Matthew W Jenner; Kevin D Boyd; David Gonzalez; Walter M Gregory; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531
View more
  5 in total

1.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 2.  Current and emerging treatment options for patients with relapsed myeloma.

Authors:  Roberto Castelli; Roberta Gualtierotti; Nicola Orofino; Agnese Losurdo; Sara Gandolfi; Massimo Cugno
Journal:  Clin Med Insights Oncol       Date:  2013-08-19

3.  Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy.

Authors:  Tianmei Zeng; Lili Zhou; Hao Xi; Weijun Fu; Juan Du; Chunyang Zhang; Hua Jiang; Jian Hou
Journal:  Stem Cells Int       Date:  2015-01-22       Impact factor: 5.443

4.  Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.

Authors:  Danilo De Novellis; Raffaele Fontana; Angela Carobene; Bianca Serio; Idalucia Ferrara; Maria Carmen Martorelli; Laura Mettivier; Roberto Guariglia; Serena Luponio; Immacolata Ruggiero; Matteo D'Addona; Tiziana Di Leo; Valentina Giudice; Carmine Selleri
Journal:  Biomedicines       Date:  2022-07-10

Review 5.  Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.

Authors:  Valentina Giudice; Francesca Mensitieri; Viviana Izzo; Amelia Filippelli; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.